Latest news
25 items- PRBright Peak Therapeutics Appoints John Schmid to its Board of DirectorsSAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ
- SECSEC Form S-1/A filed by Helix Acquisition Corp. (Amendment)S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECSEC Form S-1/A filed by Helix Acquisition Corp. (Amendment)S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECHelix Acquisition Corp. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECHelix Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECHelix Acquisition Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (Amendment)8-K/A - MoonLake Immunotherapeutics (0001821586) (Filer)
- SECSEC Form 10-Q filed by Helix Acquisition Corp.10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
- INSIDERSEC Form 4 filed by Sturge Simon4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Xavier Ramnik4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Moukheibir Catherine4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 4 filed by Phillips Andrew John4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECSEC Form S-1/A filed by Helix Acquisition Corp. (Amendment)S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)
- 13D/GSEC Form SC 13D filed by Helix Acquisition Corp.SC 13D - MoonLake Immunotherapeutics (0001821586) (Subject)
- INSIDERSEC Form 3: New insider Bvf Partners L P/Il claimed ownership of 21,691,694 units of Class A Ordinary Shares3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3: New insider Reich Kristian claimed ownership of 3,363,870 units of Class C ordinary shares3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3 filed by new insider Phillips Andrew John3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3: New insider Sturge Simon claimed ownership of 342,980 units of Class C ordinary shares3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3: New insider Santos Da Silva Jorge claimed ownership of 3,363,870 units of Class C ordinary shares3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3: New insider Bodenstedt Matthias claimed ownership of 915,376 units of Class C ordinary shares3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3 filed by new insider Xavier Ramnik3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lassen Kara3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3 filed by new insider Loy Spike3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- INSIDERSEC Form 3 filed by new insider Moukheibir Catherine3 - MoonLake Immunotherapeutics (0001821586) (Issuer)
- SECHelix Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
- INSIDERSEC Form 4: Helix Holdings Llc converted options into 2,785,000 units of Class A Ordinary Shares4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
HLXA FAQ
6 questionsWhat does Helix Acquisition Corp. do?
Helix Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Boston, Massachusetts.Where does HLXA stock trade?
Helix Acquisition Corp. (HLXA) is listed on NASDAQ.What sector and industry is HLXA in?
Helix Acquisition Corp. operates in the Finance sector, Business Services industry.When did Helix Acquisition Corp. go public?
Helix Acquisition Corp. (HLXA) completed its IPO in 2020.What companies are similar to HLXA?
Notable peers in the same industry include FLT (FleetCor Technologies Inc.), NVEI (Nuvei Corporation Subordinate Voting Shares), NLSN (Nielsen N.V.), STMP (Stamps.com Inc.), ENV (Envestnet Inc). Compare HLXA side-by-side with any of them on Quantisnow.How can I track HLXA on Quantisnow?
Quantisnow aggregates Helix Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HLXA to receive live email and push alerts on every new disclosure.